Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 17;11(1):e005940. doi: 10.1136/jitc-2022-005940

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Simvastatin and lovastatin may alter the ratio of M1:M2 macrophages. MOC1 tumor-bearing mice were treated with simvastatin/lovastatin and anti-PD-1 as in figure 3. Mice were sacrificed during the second week of treatment, then tumors were harvested and analyzed by flow cytometry for myeloid cells, including dendritic cells (A, B, CD11b+CD11c+F4/80-), and macrophages (C–F, CD11b+F4/80+), including M1-like (D, F, CD206 low) and M2-like (E, F, CD206 high) macrophages. Data are mean±SEM, n=5, *p<0.05, **p<0.01, versus control or as indicated. MOC1, mouse oral cancer; TADCs, tumor-associated dendritic cells.